Ann-Kristin Folkerts

Ann-Kristin Folkerts

Auto-generated profile, based on publicly available information

Ann-Kristin Folkerts

Medical Psychology | Neuropsychology and Gender Studies & Center for Neuropsychological Diagnostics and Intervention (CeNDI), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2019 in Journal of NeuroEngineering and Rehabilitation
Verified
Journal Article
Open access
PDF file
AGAugusto Garcia-Agundez
Augusto Garcia-Agundez
AFAnn-Kristin Folkerts
Ann-Kristin Folkerts
RKRobert Konrad
Robert Konrad
PCPolona Caserman
Polona Caserman
TTThomas Tregel
Thomas Tregel
EKElke Kalbe
Elke Kalbe
The goal of this contribution is to gather and to critically analyze recent evidence regarding the potential of exergaming for Parkinson’s disease (PD) rehabilitation and to provide an up-to-date analysis of the current state of studies on exergame-based therapy in PD patients. We performed our search based on the conclusions of a previous systematic review published in 2014. Inclusion criteria were articles published in the indexed databases Pubmed, Scopus, Sciencedirect, IEEE and Cochrane published since January 1, 2014. Exclusion criteria were papers with a target group other than PD patients exclusively, or contributions not based on exergames. Sixty-four publications out of 525 matches were selected. The analysis of the 64 selected publications confirmed the putative improvement in motor skills suggested by the results of the previous review. The reliability and safety of both Microsoft Kinect and Wii Balance Board in the proposed scenarios was further confirmed by several recent studies. Clinical trials present better (n = 5) or similar (n = 3) results than control groups (traditional rehabilitation or regular exercise) in motor (TUG, BBS) and cognitive (attention, alertness, working memory, executive function), thus emphasizing the potential of exergames in PD. Pilot studies (n = 11) stated the safety and feasibility of both Microsoft Kinect and Wii Balance Board, potentially in home scenarios as well. Technical papers (n = 30) stated the reliability of balance and gait data captured by both devices. Related meta-analyses and systematic reviews (n = 15) further support these statements, generally citing the need for adaptation to patient’s skills and new input devices and sensors as identified gaps. Recent evidence indicates exergame-based therapy has been widely proven to be feasible, safe, and at least as effective as traditional PD rehabilitation. Further insight into new sensors, best practices and different cognitive stadiums of PD (such as PD with Mild Cognitive Impairment), as well as task specificity, are required. Also, studies linking game parameters and results with traditional assessment methods, such as UPDRS scores, are required. Outcomes for randomized controlled trials (RCTs) should be standardized, and follow-up studies are required, particularly for motor outcomes.

23 February 2023 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
HJHanna Johansson
Hanna Johansson
AFAnn-Kristin Folkerts
Ann-Kristin Folkerts
IHIda Hammarström
Ida Hammarström
EKElke Kalbe
Elke Kalbe
BLBreiffni Leavy
Breiffni Leavy
Motor–cognitive training in Parkinson’s disease (PD) can positively affect gait and balance, but whether motor–cognitive (dual-task) performance improves is unknown. This meta-analysis, therefore, aimed to establish the current evidence on the effects of motor–cognitive training on dual-task performance in PD. Systematic searches were conducted in five databases and 11 studies with a total of 597 people (mean age: 68.9 years; mean PD duration: 6.8 years) were included. We found a mean difference in dual-task gait speed (0.12 m/s (95% CI 0.08, 0.17)), dual-task cadence (2.91 steps/min (95% CI 0.08, 5.73)), dual-task stride length (10.12 cm (95% CI 4.86, 15.38)) and dual-task cost on gait speed (− 8.75% (95% CI − 14.57, − 2.92)) in favor of motor–cognitive training compared to controls. The GRADE analysis revealed that the findings were based on high certainty evidence. Thus, we can for the first time systematically show that people with PD can improve their dual-task ability through motor–cognitive training.

12 June 2023 in Journal of Parkinson’s Disease
Verified
Journal Article
Open access
PDF file
AFAnn-Kristin Folkerts
Ann-Kristin Folkerts
JNJörn Nielsen
Jörn Nielsen
RGRomina Gollan
Romina Gollan
ALAnnika Lansu
Annika Lansu
DSDominik Solfronk
Dominik Solfronk
EKElke Kalbe
Elke Kalbe
Background: Fatigue is one of the most common and debilitating non-motor symptoms among patients with Parkinson’s disease (PD) and significantly impacts quality of life. Therefore, effective treatment options are needed. Objective: To provide an update on randomized controlled trials (RCTs) including pharmacological and non-pharmacological (but non-surgical) treatments that examine the effects of fatigue on PD patients. Methods: We searched the MEDLINE, EMBASE, PsycINFO, CENTRAL, and CINAHL databases for (cross-over) RCTs on pharmacological and non-pharmacological interventions for treating fatigue in PD patients until May 2021. Meta-analyses for random-effects models were calculated when two or more studies on the same treatment option were available using standardized mean differences (SMDs) with 95% confidence intervals (CIs). Results: Fourteen pharmacological and 16 non-pharmacological intervention RCTs were identified. For pharmacological approaches, a meta-analysis could only be performed for modafinil compared to placebo ( n = 2) revealing a non-significant effect on fatigue (SMD = – 0.21, 95% CI – 0.74–0.31, p = 0.43). Regarding non-pharmacological approaches, physical exercise ( n = 8) following different training approaches versus passive or placebo control groups showed a small significant effect (SMD = – 0.37, 95% CI – 0.69‐ – 0.05, p = 0.02) which could not be demonstrated for acupuncture vs. sham-acupuncture (SMD = 0.16, 95% CI – 0.19–0.50, p = 0.37). Conclusion: Physical exercise may be a promising strategy to treat fatigue in PD patients. Further research is required to examine the efficacy of this treatment strategy and further interventions. Future studies should differentiate treatment effects on physical and mental fatigue as the different underlying mechanisms of these symptoms may lead to different treatment responses. More effort is required to develop, evaluate, and implement holistic fatigue management strategies for PD patients.

30 November 2020 in Parkinson's Disease
Verified
Journal Article
Open access
PDF file
EKElke Kalbe
Elke Kalbe
AFAnn-Kristin Folkerts
Ann-Kristin Folkerts
AOAnja Ophey
Anja Ophey
CECarsten Eggers
Carsten Eggers
SESaskia Elben
Saskia Elben
ILInga Liepelt-Scarfone
Inga Liepelt-Scarfone
Background. Meta-analyses have demonstrated cognitive training (CT) benefits in Parkinson’s disease (PD) patients. However, the patients’ cognitive status has only rarely been based on established criteria. Also, prediction analyses of CT success have only sparsely been conducted. Objective. To determine CT effects in PD patients with mild cognitive impairment (PD-MCI) on cognitive and noncognitive outcomes compared to an active control group (CG) and to analyze CT success predictors. Methods. Sixty-four PD-MCI patients (age: 67.61 ± 7.70; UPDRS-III: 26.58 ± 13.54; MoCA: 24.47 ± 2.78) were randomized to either a CT group or a low-intensity physical activity CG for six weeks (twice weekly, 90 minutes). Outcomes were assessed before and after training. MANOVAs with follow-up ANOVAs and multiple regression analyses were computed. Results. Both interventions were highly feasible (participation, motivation, and evaluation); the overall dropout rate was 4.7%. Time × group interaction effects favoring CT were observed for phonemic fluency as a specific executive test ( p = 0.018 , η p 2 = 0.092 ) and a statistical trend for overall executive functions ( p = 0.095 , η p 2 = 0.132 ). A statistical trend for a time × group interaction effect favoring CG was shown for the digit span backward as a working memory test ( p = 0.098 , η p 2 = 0.043 ). Regression analyses revealed cognitive baseline levels, education, levodopa equivalent daily dose, motor scores, and ApoE status as significant predictors for CT success. Conclusions. CT is a safe and feasible therapy option in PD-MCI, yielding executive functions improvement. Data indicate that vulnerable individuals may show the largest cognitive gains. Longitudinal studies are required to determine whether CT may also attenuate cognitive decline in the long term. This trial is registered with DRKS00010186.

9 August 2024 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
EKElke Kalbe
Elke Kalbe
AFAnn-Kristin Folkerts
Ann-Kristin Folkerts
KWKarsten Witt
Karsten Witt
CBCarsten Buhmann
Carsten Buhmann
ILInga Liepelt-Scarfone
Inga Liepelt-Scarfone
FGfor the German Parkinson’s Guidelines Group
for the German Parkinson’s Guidelines Group
Background and objective: Cognitive impairment and dementia as well as affective disorders are common and debilitating syndromes that develop in people with Parkinson’s disease (PwPD). The authors summarized recommendations for the 2023 updated German guidelines on “Parkinson’s disease” from the German Neurological Society (DGN), focusing on the diagnosis and treatment of these disorders. Methods: The recommendations were based on literature reviews, other relevant guidelines, and expert opinions. Results: Measurements to assess cognitive and affective states were reviewed for psychometric properties, use in routine clinical practice, and availability in German. To improve mild cognitive impairment, cognitive training and physical aerobic training are recommended. To treat Parkinson’s disease (PD)-related dementia, cognitive stimulation (as a non-pharmacological intervention) and acetylcholinesterase inhibitors (AChEIs, i.e., rivastigmine) are recommended. Cognitive behavioral therapy is recommended to treat depression, anxiety, and fear of progression. Physical interventions are recommended to treat depression, fatigue, and apathy. Optimized dopaminergic treatment is the first-line pharmacological strategy recommended to manage depression, apathy, anhedonia, fatigue, and mood swings. Major depression can be additionally treated using venlafaxine or desipramine, while moderate depression can be treated pharmacologically according to its clinical phenotype (psychomotor retardation or agitation) and comorbidities (e.g., sleep disturbances, pain). Venlafaxine and nortriptyline can be used to treat anhedonia, while citalopram can be used for anxiety. Conclusions: In addition to the updated pharmacological treatment options, new insights into recommendations for standardized diagnostics and non-pharmacological interventions were provided for the German health care system. However, more studies are needed to explore the full potential of non-pharmacological interventions to treat and prevent cognitive impairment and affective disorders.

2 December 2018 in Parkinson's Disease
Verified
Journal Article
Open access
PDF file
AFAnn-Kristin Folkerts
Ann-Kristin Folkerts
MDMiriam E. Dorn
Miriam E. Dorn
MRMandy Roheger
Mandy Roheger
MMMarco Maassen
Marco Maassen
JKJanneke Koerts
Janneke Koerts
EKElke Kalbe
Elke Kalbe
Background. While the efficacy of cognitive stimulation (CS) has been demonstrated in patients with dementia, no study has included patients with Parkinson’s disease dementia (PDD). Objective. For the first time, this randomized crossover pilot study examined the feasibility and potential effects of CS in PDD. Methods. All residents of a PDD-specific long-term care unit in the Netherlands that were eligible for the study (n=12) were randomly allocated to group A (n=6) receiving CS (eight weeks, twice weekly for 60 minutes) or group B (n=6) receiving usual care (control group, CG). The CG participated in CS afterwards, resulting in an experimental group (EG), consisting of n=12. Pre- and postassessments and a six-week follow-up (FU) were conducted for cognition, neuropsychiatric symptoms, quality of life (QoL), and activities of daily living (ADL) outcomes. Results. Between-group analysis with difference scores from pre- to posttest revealed a group difference for global cognition (CERAD total score) favoring the EG, with a moderate effect size and a p value just failing to reach statistical significance (p=0.067; r = 0.43). A further statistical trend was observed for neuropsychiatric symptoms, again with a moderate effect size (p=0.075; r = 0.42). Within-group analyses indicated improvement only in the EG with large effects also just failing to reach significance for global cognition (short term, p=0.060; r = 0.70) as well as for depression (long term, p=0.072; r = 0.61). ADL deteriorated significantly at FU in the EG (p=0.014; r = 0.71). Conclusions. Although our data are preliminary due to the small sample size, this study shows that CS is feasible and potentially effective for cognitive and noncognitive outcomes in PDD patients. Randomized controlled trials with larger sample sizes are needed to confirm these promising results.